Anteris Technologies Global Corp. (NASDAQ:AVR) Stock Has Consensus Target Price of $14.00

Anteris Technologies Global Corp. (NASDAQ:AVR) has been given an average recommendation of “Hold” by the five brokerages that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $14.00.

AVR has been the topic of a number of analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Anteris Technologies Global in a research note on Wednesday, August 26th. Cantor Fitzgerald restated an “overweight” rating and issued a $15.00 price target on shares of Anteris Technologies Global in a research report on Wednesday. Finally, Barclays raised Anteris Technologies Global to a “hold” rating in a research note on Wednesday, October 7th.

Anteris Technologies Global Price Performance

Shares of NASDAQ AVR opened at $6.26 on Monday. The company’s 50 day simple moving average is $8.28 and its 200 day simple moving average is $8.06. Anteris Technologies Global has a fifty-two week low of $3.30 and a fifty-two week high of $11.06. The firm has a market capitalization of $610.10 million, a P/E ratio of -3.21 and a beta of 1.87.

Anteris Technologies Global (NASDAQ:AVR) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.09). Anteris Technologies Global had a negative net margin of 4,619.27% and a negative return on equity of 77.69%. The business had revenue of $1.01 million during the quarter, compared to the consensus estimate of $1.50 million. During the same period in the previous year, the business posted ($0.58) earnings per share. Sell-side analysts expect that Anteris Technologies Global will post -1.21 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, major shareholder L1 Capital Pty Ltd bought 648,455 shares of Anteris Technologies Global stock in a transaction on Monday, October 5th. The shares were purchased at an average price of $7.51 per share, for a total transaction of $4,869,897.05. Following the completion of the acquisition, the insider owned 12,778,380 shares in the company, valued at approximately $95,965,633.80. This represents a 5.35% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Over the last quarter, insiders bought 1,554,730 shares of company stock valued at $11,694,513 and sold 3,008,459 shares valued at $25,243,576. Insiders own 4.50% of the company’s stock.

Institutional Trading of Anteris Technologies Global

Hedge funds have recently modified their holdings of the company. BlackRock Inc. bought a new position in shares of Anteris Technologies Global during the second quarter worth $56,846,000. Nantahala Capital Management LLC acquired a new position in shares of Anteris Technologies Global in the 2nd quarter valued at $33,325,850. ADAR1 Capital Management LLC acquired a new position in shares of Anteris Technologies Global in the 2nd quarter valued at $30,979,000. Perceptive Advisors LLC grew its holdings in shares of Anteris Technologies Global by 104.4% in the 1st quarter. Perceptive Advisors LLC now owns 3,425,476 shares of the company’s stock valued at $19,011,000 after buying an additional 1,750,000 shares during the period. Finally, Militia Capital Management LLC bought a new stake in shares of Anteris Technologies Global in the 1st quarter valued at $3,663,000.

Anteris Technologies Global Company Profile

Anteris Technologies Global is a clinical-stage structural heart company developing technologies intended to treat aortic valve disease. The company’s lead product is the DurAVR transcatheter heart valve, which is designed to replicate the performance characteristics of a healthy human aortic valve and restore more natural blood flow.

Anteris uses its proprietary ADAPT tissue-engineering technology to create heart-valve materials designed for durability and biocompatibility. The company is focused primarily on transcatheter aortic valve replacement and related structural-heart applications, with its products progressing through clinical development and regulatory evaluation rather than broad commercial distribution.

The company has Australian origins and maintains operations and clinical-development activities in both Australia and the United States.